MX2019014302A - Agente para prevenir o tratar la ataxia espinocerebelosa. - Google Patents

Agente para prevenir o tratar la ataxia espinocerebelosa.

Info

Publication number
MX2019014302A
MX2019014302A MX2019014302A MX2019014302A MX2019014302A MX 2019014302 A MX2019014302 A MX 2019014302A MX 2019014302 A MX2019014302 A MX 2019014302A MX 2019014302 A MX2019014302 A MX 2019014302A MX 2019014302 A MX2019014302 A MX 2019014302A
Authority
MX
Mexico
Prior art keywords
prevent
treat
ataxia
agent
spinocerebellous
Prior art date
Application number
MX2019014302A
Other languages
English (en)
Other versions
MX393700B (es
Inventor
Tomohiro Okuda
Hiroshi Kobayashi
Yoshihiko Matsumoto
Original Assignee
Fujifilm Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Toyama Chemical Co Ltd filed Critical Fujifilm Toyama Chemical Co Ltd
Publication of MX2019014302A publication Critical patent/MX2019014302A/es
Publication of MX393700B publication Critical patent/MX393700B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se dirige al problema de proporcionar un agente terapéutico o profiláctico superior para la ataxia espinocerebelosa. El 1-(3-(2-(1-benzotiofen-5-il)etoxi)propil)azet idin-3-ol o una sal del mismo tiene un efecto de supresión de la atrofia cerebral, en particular, la atrofia cerebelosa, y por consiguiente es útil como un agente terapéutico o profiláctico para la ataxia espinocerebelosa. Por lo tanto, es posible prevenir o tratar la atrofia cerebelosa observada en la ataxia espinocerebelosa por medio de la administración del 1-(3-(2-(1-benzotiofen-5-il)etoxi)propil)azetidin-3-ol o una sal del mismo.
MX2019014302A 2017-06-02 2018-06-01 Agente para prevenir o tratar la ataxia espinocerebelosa. MX393700B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2017109885 2017-06-02
JP2017128472 2017-06-30
JP2017145101 2017-07-27
PCT/JP2018/021224 WO2018221730A1 (ja) 2017-06-02 2018-06-01 脊髄小脳変性症予防または治療剤

Publications (2)

Publication Number Publication Date
MX2019014302A true MX2019014302A (es) 2022-07-05
MX393700B MX393700B (es) 2025-03-24

Family

ID=64454849

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014302A MX393700B (es) 2017-06-02 2018-06-01 Agente para prevenir o tratar la ataxia espinocerebelosa.

Country Status (15)

Country Link
US (1) US11660287B2 (es)
EP (1) EP3632430A4 (es)
JP (1) JP7133547B2 (es)
KR (1) KR20190138696A (es)
CN (1) CN110691593B (es)
AU (1) AU2018277981B2 (es)
BR (1) BR112019024881A2 (es)
CA (1) CA3067455C (es)
IL (1) IL270910B2 (es)
MX (1) MX393700B (es)
NZ (1) NZ759647A (es)
RU (1) RU2728717C1 (es)
SG (1) SG11201911515QA (es)
WO (1) WO2018221730A1 (es)
ZA (1) ZA201907974B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190137936A (ko) 2017-06-02 2019-12-11 후지필름 도야마 케미컬 가부시키가이샤 뇌 위축 예방 또는 치료제
US11541033B2 (en) 2017-06-02 2023-01-03 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating Alzheimer's disease
MX393006B (es) 2017-06-02 2025-03-24 Fujifilm Toyama Chemical Co Ltd Agente para reducir la cantidad de proteina beta amiloide.
JP7227914B2 (ja) 2017-10-30 2023-02-22 富士フイルム富山化学株式会社 エモパミル結合タンパク質結合剤およびその利用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0722731B1 (en) * 1994-08-05 2002-06-05 Suntory Limited Remedy for spinocerebellar degeneration
WO1999011293A1 (en) 1997-09-05 1999-03-11 Human Genome Sciences, Inc. 50 human secreted proteins
GB9824207D0 (en) 1998-11-04 1998-12-30 Zeneca Ltd Neurological disorders
BRPI0213393B8 (pt) 2001-10-19 2021-05-25 Fujifilm Toyama Chemical Co Ltd derivados de éter alquílico, ou um de seus sais, processo para produzir um derivado de éter alquílico, derivado de alquil-amida, ou um de seus sais, e, composição farmacêutica
HUE041842T2 (hu) 2002-06-14 2019-05-28 Toyama Chemical Co Ltd Gyógyászati készítmény agymûködés javítására
ES2391273T3 (es) 2003-04-17 2012-11-23 Toyama Chemical Co., Ltd. Agente preventivo/curativo para enfermedades del nervio retiniano que contiene derivados de éter alquílico o sus sales
JP5196641B2 (ja) * 2004-09-09 2013-05-15 塩野義製薬株式会社 脊髄小脳変性症治療剤
TWI350754B (en) * 2004-09-09 2011-10-21 Shionogi & Co A pharmaceutical composition for treating spinocerebellar ataxia
US8119625B2 (en) * 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
CA2648898C (en) * 2006-04-26 2015-01-20 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
EA017842B1 (ru) * 2008-03-04 2013-03-29 Вернэлис (Р&Д) Лтд. Производные азетидина и их применение
FR2934596B1 (fr) 2008-07-30 2015-04-10 Trophos Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
WO2011057199A1 (en) * 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
BR112014020434B1 (pt) 2012-02-22 2021-10-13 Fujifilm Toyama Chemical Co., Ltd. Composição farmacêutica sólida
WO2014015157A2 (en) 2012-07-19 2014-01-23 Philadelphia Health & Education Corporation Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
JP5947465B2 (ja) 2012-10-01 2016-07-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ活性剤としてのベンズイミダゾール類
BR112016017747A2 (pt) * 2014-01-31 2017-08-08 Toyama Chemical Co Ltd Agente de intensificação de efeito de reabilitação pós lesão de nervo compreendendo derivados de éter de alquila ou sal do mesmo
WO2015163318A1 (ja) 2014-04-25 2015-10-29 レジリオ株式会社 アルツハイマー病の治療剤を含む、神経細胞の軸索の機能不全が関与する疾患の治療剤
WO2015188368A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
WO2016051799A1 (ja) 2014-10-01 2016-04-07 学校法人同志社 ２－アミノヒドロキノン誘導体及びタウ凝集阻害剤
EA036518B1 (ru) 2015-02-02 2020-11-18 Юсб Байофарма Спрл Производные 9h-пирролодипиридина
US20160324851A1 (en) 2015-05-07 2016-11-10 Axovant Sciences, Ltd. Methods of treating a neurodegenerative disease
US10238632B2 (en) 2015-06-11 2019-03-26 Fujifilm Toyama Chemical Co., Ltd. Sigma receptor-binding agent
CA3009152C (en) 2015-12-25 2023-08-15 Toyama Chemical Co., Ltd. Tablet comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salt thereof
JP7370859B2 (ja) 2017-06-02 2023-10-30 富士フイルム富山化学株式会社 タウオパチー予防または治療剤
MX393006B (es) 2017-06-02 2025-03-24 Fujifilm Toyama Chemical Co Ltd Agente para reducir la cantidad de proteina beta amiloide.
US11541033B2 (en) 2017-06-02 2023-01-03 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating Alzheimer's disease
KR20190137936A (ko) 2017-06-02 2019-12-11 후지필름 도야마 케미컬 가부시키가이샤 뇌 위축 예방 또는 치료제
JP7227914B2 (ja) 2017-10-30 2023-02-22 富士フイルム富山化学株式会社 エモパミル結合タンパク質結合剤およびその利用

Also Published As

Publication number Publication date
CA3067455A1 (en) 2018-12-06
EP3632430A1 (en) 2020-04-08
MX393700B (es) 2025-03-24
WO2018221730A1 (ja) 2018-12-06
IL270910A (en) 2020-01-30
IL270910B1 (en) 2023-11-01
JP7133547B2 (ja) 2022-09-08
IL270910B2 (en) 2024-03-01
CN110691593A (zh) 2020-01-14
JPWO2018221730A1 (ja) 2020-04-09
CN110691593B (zh) 2023-05-02
CA3067455C (en) 2021-11-23
ZA201907974B (en) 2022-03-30
AU2018277981B2 (en) 2021-04-08
US20200085787A1 (en) 2020-03-19
US11660287B2 (en) 2023-05-30
EP3632430A4 (en) 2020-06-10
AU2018277981A1 (en) 2019-12-19
RU2728717C1 (ru) 2020-07-30
NZ759647A (en) 2022-02-25
SG11201911515QA (en) 2020-01-30
BR112019024881A2 (pt) 2020-06-16
KR20190138696A (ko) 2019-12-13

Similar Documents

Publication Publication Date Title
NZ770260A (en) Substituted heterocyclic inhibitors of ptpn11
EA201500953A1 (ru) 3-ацетиламино-1-(фенилгетероариламинокарбонил или фенилгетероарилкарбониламино)бензольные производные для лечения гиперпролиферативных нарушений
MX2018000412A (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2).
MX2019014041A (es) Inhibidores pirazolicos de magl.
PY1218707A (es) Combinaciones de compuestos activos que comprenden un derivado de (tio) carboxamida y un compuesto fungicida
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
MX2019014302A (es) Agente para prevenir o tratar la ataxia espinocerebelosa.
EA201990044A1 (ru) Гетероциклические соединения в качестве антибактериальных средств
JOP20210158A1 (ar) مُعَدِّلات التعبير الجيني عن hsd17b13
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
CL2016002497A1 (es) “compuestos derivados de heterociclos condensados sustituidos, moduladores de gpr119; composición farmacéutica que los comprende; útiles en el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados”. pct
JOP20200252B1 (ar) مركبات مساعدة لعامل تمايز النمو 15 وطرق استخدامها
MX2017012545A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
MX2020006191A (es) Bacteriocinas terapeuticas.
MX393052B (es) Agente para prevenir o tratar atrofia cerebral.
AR077372A1 (es) Composiciones y metodos para tratar infecciones oftalmicas oticas o nasales
CL2019000857A1 (es) Compuestos heterocíclicos y su uso para prevenir o tratar las infecciones bacterianas.
MX2022001764A (es) Composiciones que comprenden tigolaner para el control de parasitos.
MX388378B (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos.
MX394436B (es) Agente para prevenir o tratar la tauopatia.
MX2017012535A (es) Compuestos hetorociclicos novedosos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
BR112017012799A2 (pt) combinações de composto ativo que compreendem um derivado de (tio)carboxamida e composto(s) fungicida(s).
MX2017014080A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
ZA202003281B (en) Heterocycle substituted pyridine derivative antifungal agents